EndoSonics plans to begin brachytherapy trial:
This article was originally published in Clinica
EndoSonics, a developer of catheter-based ultrasound systems, has applied to the US FDA for approval to begin a trial of an ultrasound-guided intravascular brachytherapy device. The Rancho Cordova, California-based company has been developing the device, called BRIGADE (beta radiation with IVUS guidance and directed energy), in conjunction with researchers at the Cleveland Clinic Foundation in Ohio. The Phase I trial will be headed by the clinic's Dr Patrick Whitlow. According to EndoSonics, the success of coronary brachytherapy depends on optimal delivery of radiation to the entire vessel wall.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.